Deal snapshot: Preparing for submission and potential approval and launch of its Phase III sleep apnea drug, Apnimed is divesting its half of Shionogi-Apnimed Sleep Science for $100m.

Pfizer, which licensed the candidate from Valneva, said the vaccine demonstrated clinically meaningful efficacy for preventing Lyme disease, even though the study failed to accrue enough cases.

For $650m up front, Collegium will pair Azstarys, which provides both immediate and extended onset of action, with Jornay PM, its ADHD drug indicated for bedtime dosing.

Since being taken private by B-FLEXION, Paratek has been building out its commercial portfolio and Radius’s osteoporosis drug Tymlos will advance that strategy.

Structure reported new weight-loss data for oral GLP-1 aleniglipron and showed that a 2.5mg starting dose can mitigate tolerability issues seen in earlier results.

Plus deals involving Rapport/Tenacia, Servier/Kyron.bio, Pfizer/Aska, TransCode/Unleashed Immune Oncolytics, Gedeon Richter/Celmatix and recent AI/ML-focused alliances.